Market Overview

Zalicus and Hydra Collaborate to Advance Novel Ion Channel Product Candidates for the Treatment of Pain


Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases and Hydra Biosciences, Inc., a leader in the discovery and development of novel ion channels, today announced that they have entered into a collaboration to advance development of Zalicus' preclinical ion channel modulator product candidates for the treatment of pain.

Posted-In: News FDA


Related Articles (ZLCS)

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial

comScore Releases January U.S. Search Engine Rankings; Google Sites Leading

NetLogic Microsystems Sees Q4 Revenue of $96.2M vs $110.6M Est